argenx SE is a clinical-stage biotechnology company that focuses on the discovery and development of antibody-based therapies for the treatment of cancer and autoimmune diseases. The company's proprietary SIMPLE Antibody platform enables the creation of differentiated therapeutic antibodies that can target multiple disease targets. argenx is headquartered in Breda, Netherlands and was founded in 2008.